Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

Neurol Sci. 2002 Apr;23(1):41-3. doi: 10.1007/s100720200022.

Abstract

As cholinergic mechanisms may be at least partially responsible for hallucinations and delusions in Parkinson's disease (PD), we conducted an open study in 8 PD patients to assess the efficacy and tolerability of the cholinesterase inhibitor donepezil, 5 mg at bedtime for two months, in the treatment of these complications. Hallucinations and delusions improved significantly in all patients. Donezepil was overall well tolerated, but a deterioration in motor disability was noted in 2 out of 8 patients.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Basal Nucleus of Meynert / drug effects
  • Basal Nucleus of Meynert / pathology
  • Basal Nucleus of Meynert / physiopathology
  • Cholinergic Fibers / drug effects
  • Cholinergic Fibers / metabolism
  • Cholinergic Fibers / pathology
  • Cholinesterase Inhibitors / adverse effects
  • Cholinesterase Inhibitors / therapeutic use*
  • Delusions / complications*
  • Delusions / drug therapy*
  • Delusions / physiopathology
  • Donepezil
  • Female
  • Hallucinations / complications*
  • Hallucinations / drug therapy*
  • Hallucinations / physiopathology
  • Humans
  • Indans / adverse effects
  • Indans / therapeutic use*
  • Male
  • Movement / drug effects
  • Parkinson Disease / complications*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Piperidines / adverse effects
  • Piperidines / therapeutic use*
  • Sexual Dysfunctions, Psychological / drug therapy
  • Sexual Dysfunctions, Psychological / etiology
  • Sexual Dysfunctions, Psychological / physiopathology
  • Sleep Wake Disorders / drug therapy
  • Sleep Wake Disorders / etiology
  • Sleep Wake Disorders / physiopathology
  • Treatment Outcome

Substances

  • Cholinesterase Inhibitors
  • Indans
  • Piperidines
  • Donepezil